epirubicin has been researched along with Diabetes Mellitus, Type 2 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, C; Li, X; Qi, X; Sun, F | 1 |
| Geng, C; Shi, J; Sun, F | 1 |
| Böhm, S; Brändle, M; Gillessen, S; Hess, D | 1 |
| Chang, WL; Chao, TC; Gau, JP; Liu, YC | 1 |
2 trial(s) available for epirubicin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotonic Agents; Cardiotoxicity; Cyclophosphamide; Dexrazoxane; Diabetes Mellitus, Type 2; Drug Monitoring; Epirubicin; Female; Heart Function Tests; Humans; Middle Aged; Treatment Outcome | 2015 |
Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes.
Topics: Antineoplastic Agents; Autonomic Nervous System; Breast Neoplasms; Dexrazoxane; Diabetes Mellitus, Type 2; Epirubicin; Female; Heart; Humans; Middle Aged; Prospective Studies | 2016 |
2 other study(ies) available for epirubicin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib.
Topics: Aged; Antibiotics, Antineoplastic; Blood Glucose; Diabetes Mellitus, Type 2; Epirubicin; Humans; Hypoglycemic Agents; Indazoles; Male; Prostatic Neoplasms; Pyrimidines; Sulfonamides | 2010 |
Primary bone lymphoma of the shoulder.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Diabetes Mellitus, Type 2; Epirubicin; Female; Humans; Humerus; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Middle Aged; Osteolysis; Prednisolone; Radiography; Rituximab; Vincristine | 2012 |